



RESEARCH ARTICLE

Evaluation of the Inhibitory Effects of Coumermycin A1 on the Growth of *Theileria* and *Babesia* Parasites *in vitro* and *in vivo*

Mahmoud AbouLaila^{1,2}, Amer Ragheb AbdEl-Aziz³, Soad Menshawy², Naoaki Yokoyama¹, Ikuo Igarashi¹, Mohammad Al-Wabel⁴ and Mosaab Omar^{4,5*}

¹National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-Cho, Obihiro, Hokkaido 080-8555, Japan; ²Department of Parasitology, Faculty of Veterinary Medicine, Damanshour University, Damanshour 22511, Elbehera, Egypt; ³Department of Parasitology, Faculty of Veterinary Medicine, Sohag University, Sohag, Egypt; ⁴Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Qassim University, Buraydah, 51452 Qassim, Saudi Arabia; ⁵Department of Parasitology, Faculty of Veterinary Medicine, South Valley University, Qena 83523, Qena, Egypt

*Corresponding author: mousaab.omr@vet.svu.edu.eg

ARTICLE HISTORY (21-058)

Received: February 04, 2021
Revised: August 05, 2021
Accepted: August 29, 2021
Published online: August 31, 2021

Key words:

B. bovis
Coumermycin A1
in vitro
in vivo
RT-PCR
T. equi

ABSTRACT

Coumermycin A1, a coumarin antibiotic, has anticancer, antibacterial, antiviral, and antimalarial activities. We aimed to evaluate the anti-thielerial and anti-babesial activity of coumermycin A1 in mice *in vivo*. Coumermycin A1 efficacy was determined by the transcription of DNA gyrase, a type II DNA topoisomerase using reverse transcriptase-polymerase chain reaction (RT-PCR) transcription. Coumermycin A1 significantly inhibited the development of preliminary parasitemia (1%). *Theileria equi* and the *Babesia* species *B. bigemina*, *B. bovis*, and *B. caballi* were observed with IC₅₀ values of 80, 70, 57, and 65 nM, respectively. Their development was remarkably inhibited at observed concentrations of 10, 25, 50, and 100 μM for the studied organisms *T. equi*, and the *Babesia* species *B. caballi*, *B. bovis* and *B. bigemina*, respectively. In the subsequent viability test, parasite re-growth was suppressed at 100 μM for *B. bigemina* and *B. bovis* and at 50 μM for *B. caballi* and *T. equi*. Coumermycin A1 Treatment of *B. bovis* cultures with Coumermycin A1 completely suppressed the transcription of the DNA gyrase subunits B and A genes. In BALB/c mice, the development of *Babesia microti* was inhibited by 70.73% using 5 mg/kg of Coumermycin A1.

To Cite This Article: AbouLaila M, AbdEl-Aziz AR, Menshawy S, Yokoyama N, Igarashi I, Al-Wabel M and Omar M, 2021. Evaluation of the inhibitory effects of coumermycin A1 on the growth of *Theileria* and *Babesia* parasites *in vitro* and *in vivo*. Pak Vet J, 41(4): 469-474. <http://dx.doi.org/10.29261/pakvetj/2021.064>

INTRODUCTION

Theileria and *Babesia* are the most common tick-borne blood parasites in animals, which provoke substantial economic losses to animal farms worldwide. *Babesia* parasites stimulate clinical syndromes like hemolytic anemia, fever, hemoglobinuria, jaundice, and edema. *Babesia* species, which are primarily common in tropical and sub-tropical regions, cause severe economic damage in the livestock industries in these areas (Jabbar *et al.*, 2000; Ica *et al.*, 2007; AbouLaila *et al.*, 2020). Piroplasmosis in equines, caused by tick-borne protozoa *T. equi* and *B. caballi*, is blamed for huge economic losses in the equine industry (Balkaya *et al.*, 2010; AbouLaila *et al.*, 2020). *Babesia microti* infects humans and rodents in several areas, like USA, and Pakistan (Akram *et al.*, 2019). Many anti-babesial drugs have been used for

several years without success due to their toxic effects (Vial and Gorenflot, 2006). Therefore, novel anti-babesiosis medications with high parasite specificity and minimal host toxicity are urgently needed. Coumarins have 3-amino-4-hydroxy coumarin and a replaced deoxysugar molecule called noviose, which is required for their biological activities (Li *et al.*, 2002). Coumermycin A1 comprises two of the coumarin-noviose nuclei that are connected via a 3-methyl-2, 4-dicarboxyl pyrrole connector. It is a potent inhibitor of subunit B of the DNA gyrase enzyme in *Plasmodium* species (Divo *et al.*, 1988; Khor *et al.*, 2005). Moreover, it is an effective C-terminal inhibitor of 90 kDa heat shock proteins (Hsp90) in cancer cells and exhibits antiviral activity (Burlison and Blagg 2006; Vozzolo *et al.* 2010; Kusuma *et al.* 2011). Coumermycin A1 has anticancer (Topcu, 2001), antibacterial (Nichterlein and Hof, 1991), antiviral

(Vozzolo, *et al.*, 2010), and antimalarial activities (Bonilla, 2008). In the basis of current reports on the fluoroquinolones efficacy in Malaria treatment (Bonilla, 2008), *Babesia*, and *Theileria* (Omar *et al.*, 2016), we assessed in this work whether the coumermycin A1 can inhibit *Babesia* and *T. equi* asexual cycle *in vitro*.

MATERIALS AND METHODS

Chemical reagents: Coumermycin A1 (from Sigma-Aldrich USA) and a stock solution of 100mM DMSO (dimethyl sulfoxide) were stored at -30°C before their use. Diminazene aceturate, an anti-infective medication [(Ganaseg) (Ciba-Geigy Japan Ltd., Tokyo, Japan)], was dissolved within double-distilled water (DDW) as a positive control to obtain a 10mM operating stock solution and keep it at -30°C.

***Babesia microti* and mice:** *B. microti* (Munich strain) was maintained in the laboratory through serial passage in BALB/c mice (AbouLaila *et al.*, 2010). The BALB/c mice (thirty-two-month-old females) were obtained from the CLEA Japan Laboratory supply Company (Tokyo, Japan) to perform *in vivo* experiments.

In vitro Babesia cultivation: The chemotherapeutic effect of Coumermycin A1 against *Babesia* strains was assessed, including Texas strain *B. bovis*, Argentina strain *B. bigemina* and *B. caballi*. The species *T. equi* (Agriculture Department of the United States) was also examined in the present study (Bork *et al.*, 2004). The parasites were cultured using either equine or bovine RBCs in a continuous microaerophilic fixed phase culture process. We used 60 U/ml of penicillin G, 60 µg/ml of streptomycin antibiotics, and 0.15 µg/ml of amphotericin B, and growth media (all from Sigma-Aldrich, Tokyo, Japan), which were complemented with equine or bovine serum.

For the *T. equi* culture, 13.6 mg/ml of hypoxanthine (ICN Biomedicals, Inc., Aurora, OH) was used as a supplement. For *B. RPMI 1640* culture media was used for *B. caballi*, 40% horse serum, amphotericin B, and antibiotics were added as supplements (AbouLaila *et al.*, 2010).

Assay on *in vitro* inhibition of growth: From cultures with 5% parasitemia, the *Babesia* species (*B. bigemina*, *B. bovis*, *B. caballi*) and *T. equi* were derived. They were then diluted to a starting parasitemia of 1% by using new red blood cells for the assays, the assay was done as mentioned in previous reports (Bork *et al.*, 2004; AbouLaila *et al.*, 2020). Using 96-well culture plates containing a 20 µl inoculum of pressed RBCs and 200µl of specific culture medium (with 0.1, 1, 5, 10, 25, 50, and 100 µM of coumermycin A1). Diminazene aceturate was used at 5, 10, 50, 100, 1000, or 2000nM (AbouLaila *et al.*, 2010). For the negative control, cultures containing only solvents were developed (DMSO 0.01% for coumermycin A1 and double-distilled water (0.02%) for Diminazene aceturate). This procedure was performed three times in three triplicate wells. The cultures were maintained at 37°C in an atmosphere of 5% oxygen, 5% carbon dioxide, and 90% nitrogen gas (N₂). Daily supplementation of the

culture medium was provided for four days by 200µl of the new medium, which contained the appropriate concentration of medication. Levels of parasitemia were determined using 1,000 Giemsa-stained smears of RBCs. On day 3 of *in vitro* culture, the 50% inhibitory concentration was determined using a curve-fitting technique called interpolation.

Testing viability: After day 4 of therapy, 6µL of uninfected equine or bovine RBCs were added to 14µL of previously treated RBC culture in 200 µl of a new growth medium. This medium was replaced daily for 10 days to determine the parasite's revival through microscopic evaluation (AbouLaila *et al.*, 2010).

Effects of Coumermycin A1 on Host Erythrocytes: Toxic effects of coumermycin A1 on host RBCs have been previously assessed (AbouLaila *et al.*, 2020). 100 µM coumermycin A1 was incubated with equine and bovine RBCs for three hours at 37°C. Then, RBCs were washed multiple times with drug-free media for 72 hours for the *Babesia* parasite cultivation process. Non-treated control cells were performed in the same way as the pre-treated group. The growth of *Babesia* and *Theileria* parasites in the pre-treated RBCs was noticed and then compared to the non-treated control cells.

Reverse Transcription Polymerase Chain reaction and Nucleic Acids Extraction: RT-PCR was determined the coumermycin A1 effect on the transcription of DNA gyrase subunits A and B genes (AbouLaila *et al.*, 2012). Cultivation (24 well culture plates) of *B. bovis* was performed using bovine erythrocytes. Cultures were treated with coumermycin A1 (IC₉₉) for eight hours (AbouLaila *et al.*, 2012). The control group (negative) cultures contained only dimethyl sulfoxide (DMSO) 0.001% and were devoid of medication. After collecting erythrocytes from three wells, they were cleansed with phosphate-buffered saline (PBS) and centrifuged at 3000 rpm for five minutes. RNA was recovered entirely using the TRI® chemical reagent (Sigma-Aldrich, USA), and its concentrations were determined spectrophotometrically (Thermo Fisher Scientific, Inc., USA) and stored at -80°C in a freezer.

RT-PCR was done by PrimeScript™ One-Step RT-PCR Kit Version 2 (Takara, Japan). Exactly 150 ng total RNA was obtained from both treated and control cultures and used to amplify (1) the A and B subunits of DNA gyrase of *B. bovis* and (2) the tubulin beta chain gene of *B. bovis* (AbouLaila *et al.*, 2012) to control the targeted genes transcription in both cultures. The reverse-transcription reaction was conducted in a reaction volume of 50 µL at 50°C for 30 minutes. The procedure included the following steps: (1) denaturation for 2 minutes at 94°C, followed by 30 denaturation cycles at 94°C for 30 seconds; (2) primer annealing for 30 seconds at 50°C, 60°C and 54°C for gyrase A/B and tubulin beta genes; (3) primer annealing for either 3 minutes for the elongation of gyrase A/B or 2 minutes for the elongation of the tubulin beta chain genes at 72°C and (4) after staining with ethidium bromide, all PCR products were electrophoresed on a 2% agarose gel and observed on a UV transilluminator using a 1000 base pair DNA ladder marker.

Assay of *in vivo* growth inhibition: The *in vivo* test of coumermycin A1 inhibition of *B. microti* was assessed twice in BALB/c mice, as previously described with some slight variation (AbouLaila *et al.*, 2010). Briefly, fifteen BALB/c female mice, eight-week-old, were divided into three groups of five and received intraperitoneally 1×10^7 *B. microti* infected RBCs. The subjects were observed, and once parasitemia reached 1%, they received treatment daily until the fifth day.

Dimethyl sulfoxide (DMSO) was used to dissolve the drugs (3% for coumermycin A1) and double-distilled water (DDW) (Diminazene aceturate 12.5%). Before injection, the phosphate buffer solution was diluted. For the negative control group, DMSO in phosphate buffer solution was administered (0.02%). In the first category, five mg/kg of coumermycin A1 was infused intraperitoneally in a 0.3 ml buffer solution (phosphate), whereas the second group received an intraperitoneal injection containing 0.3 ml of PBS involving 0.013% DDW. The third group received subcutaneous administration of Diminazene aceturate 25 mg/kg (Ganaseg, Japan Ciba-Geigy, Ltd.) in 0.1 ml DDW (AbouLaila *et al.*, 2010).

Parasitemia was monitored daily for up to 20 days following infection using 1,000 RBCs in Giemsa-stained smears. All animal studies have been performed in compliance with the National Research Center for Protozoan Diseases' Experimental Animal Care and Management Standard.

Statistical analysis: The student's t-test determined significance in the statistical analysis using the JMP software program (SAS Institute, Inc., USA). This program was used for the statistical analysis of all data in this study. The threshold for statistical significance was set to $P < 0.005$.

RESULTS

***In vitro* growth inhibition:** Coumermycin A1 significantly inhibited parasitemia for all the studied strains at a concentration of $0.1 \mu\text{M}$ (Fig. 1). Growth was suppressed on day 3, at concentrations of $100 \mu\text{M}$ (*B. bovis*, *B. bigemina*), $25 \mu\text{M}$ (*B. caballi*), and $10 \mu\text{M}$ (*T. equi*). Coumermycin A1 eliminated all *Babesia* species on day 3 and *T. equi* on day 1 of drug exposure at $100 \mu\text{M}$. *In vitro* parasitic growth was found to be significantly suppressed by 5nM of Diminazene aceturate treatment ($P < 0.05$). Diminazene aceturate suppressed parasites at a concentration of 2000nM, whereas 50nM was needed to inhibit *B. caballi* expansion. For ten days following medication withdrawal, parasites did not appear at 50 (*B. bovis*), 25 (*B. caballi*), 100 (*B. bigemina*), and $10 \mu\text{M}$ (*T. equi*). *Babesia* species exposed to lower medication concentrations resumed growth once the medication was withdrawn; this was determined by enhanced parasitemia observed under a microscope. Parasites exposed to diminazene aceturate showed no regeneration at $25 \mu\text{M}$ (*B. caballi*) or $1000 \mu\text{M}$ concentrations (*B. bovis*, *T. equi*,




Fig. 1: Graphs depicting the *in vitro* coumermycin A1 inhibitory effects on growth at different concentrations (A) *B. bovis*, (B) *B. bigemina*, (C) *B. caballi* and (D) *T. equi*. Each of the values is expressed as mean \pm SD. The curves demonstrate the findings of the 3 triplicate studies. An asterisk denotes any significant difference between coumermycin A1 treated and untreated cultures. Regrowth was determined as viability (+) after 10 days; death is denoted by (-).

Table 1: The 50% inhibitory concentration values of coumermycin A1 and diminazene aceturate for the parasites *T. equi* and the *Babesia* species *B. bovis*, *B. bigemina*, and *B. caballi*.

	IC ₅₀ (nM) ^a	
	Coumermycin A1	Diminazene
<i>B. bovis</i>	70±1	300±30
<i>B. bigemina</i>	80±2	190±20
<i>B. caballi</i>	65±8	10±2
<i>T. equi</i>	57±3	710±15

^a The 50% inhibitory concentration values are represented as drug concentrations in the nanomolar growth medium. It was calculated using a curve fitting technique on the 4th day of the *in vitro* culture. IC₅₀ values are reported as mean and SD for the 3 different experiments. ^b Divo *et al.* 1988; ND not determined

and *B. bigemina*). The IC₅₀ values for diminazene and Coumermycin A1 are shown in Table 1. The DMSO-treated group grew similarly to the control group within the cultures. The morphology of parasites in treated and untreated cultures was compared. Coumermycin A1 causes the parasites to swell without cytoplasm in *B. bovis* cultures (Fig. 2B), which corresponds to the DMSO group's typical morphology (Fig. 2A). Compared to standard parasites in the DMSO-negative control cultures, parasites appeared degenerated in coumermycin A1-treated *B. bigemina* (Fig. 2C), *B. caballi* (Fig. 3B), and *T. equi* (not presented) cultures. Coumermycin A1 was found to be safe and nontoxic to host red blood cells (RBCs), even at the highest concentration (100µM), as the negative control group had parasitemia comparable to that of untreated erythrocytes (not presented).

RT-PCR: The coumermycin A1 at IC₉₉ concentration can inhibit mRNA transcripts of the DNA gyrase subunit B and subunit A genes in cultured *B. bovis*, but not in untreated parasites. The treatment possessed no consequence on the tubulin beta chain gene transcripts.

***In vivo* effects of Coumermycin A1 on *B. microti*:**

There was a significant decrease in the parasitemia level in the treated group compared to the untreated group ($P < 0.05$) between days 3 and 7 post-infection (Figure 4). The highest level of parasitemia (5.4%) was observed on the fifth day following infection when treated with diminazene aceturate (25 mg/kg), and 12.75% on the seventh day following infection when treated with 5 mg/kg coumermycin A1. Parasitemia was found to be 43.6% in the untreated group (DMSO) on the sixth day post-infection (Fig. 4).

DISCUSSION

This work revealed that coumermycin A1 provoked a significant *in vitro* inhibition of the development of three *Babesia* species. Moreover, when *T. equi* parasites were exposed to higher drug concentrations, they were completely suppressed. *T. equi* was found to be more sensitive to coumermycin A1 compared to the three *Babesia* species.

In this study, the coumermycin A1 showed lower IC₅₀ values for *T. equi* and *Babesia* species than those of Diminazene aceturate, except for *B. caballi*. Coumermycin A1 had an IC₅₀ value of 28 µM for *Plasmodium falciparum* (Divo *et al.*, 1988), which was higher than the IC₅₀ values for *T. equi* and *Babesia* species.




Fig. 2: These are light microscopic slides depicting coumermycin A1 (10 µM) treated cultures of; (A) *B. bovis* (control) and (B) treated, and (C) *B. bigemina* control while (D) represents the treated group. Treated cultures demonstrated an increased number than control cultures of swollen and degenerated parasites shown by arrows. Micrographs were drawn on day three of the procedure: bars scale, 10µM.




Fig. 3: Light micrographic images of *in vitro B. caballi* cultures treated with 10µM coumermycin A1. Image (A) represents the control group, and (B) is the coumermycin A1-treated cultures. Cultures treated with the medication a higher number of swollen and degenerated parasites shown by arrows when compared to the control (negative) group. Micrographs on the third day of therapy were taken. Scale bars, 10µM.




Fig. 4: This graph depicts the inhibitory effects of intraperitoneal infusion of diminazene aceturate 25 mg/kg and 5 mg/kg s.c coumermycin A1 in five mice that were part of the experimental community on the *in vivo* growth of *Babesia microti*. Values are represented as mean and standard deviation. An asterisks represents substantial differences (Student t-test; * $P < 0.01$). Post-inoculation between control groups treated with coumermycin A1 and dimethyl sulfoxide from days 3 to 7. The double-headed arrow indicates rehabilitation days.

The 50% inhibitory concentration values of coumermycin A1 for *T. equi* and the *Babesia* species were found to be lower than previously tested antibabesial therapy (Bork *et*

al., 2004; Aboulaila *et al.*, 2010, 2012, 2014; Munkhjargal *et al.*, 2012; Salama *et al.*, 2014; Omar *et al.*, 2016; Rizk *et al.*, 2017; Batiha *et al.*, 2020). The effectiveness of Coumermycin A1 (IC₅₀ values) on *T. equi* and *Babesia* species was found to be comparable to that of other medications including, luteolin (Aboulaila *et al.*, 2019a), atovaquone (Matsuu *et al.*, 2008), epoxomicin (Aboulaila *et al.*, 2010), quinuronium sulfate (Brockelman and Tan-Ariya, 1991), and imidocarb dipropionate (Rodriguez and Trees, 1996). Coumermycin A1 had a higher IC₅₀ value than quercetin (Aboulaila *et al.*, 2019c) and enrofloxacin (Aboulaila *et al.*, 2019b).

Coumermycin A1 was observed to be safe for bovine and equine red blood cells when used to treat erythrocytes, with the main concentration used in the experiment demonstrating no difference in growth outline and host cell morphology, size, and color using a light microscope. Furthermore, IC₅₀ of coumermycin A1 for parasites was determined to be in nanomolar, indicating that it has no detectable cytotoxicity at the concentration of 10 µM for both Human chronic myelogenous leukemia K562 and embryonic kidney 293A cells, as determined by cell growth and transient CMV-GFP constructs (Zhao *et al.*, 2003). Moreover, a concentration of 20 µg/ml initiates the toxic effects on these cells (Zhao *et al.*, 2003).

The calculated 99% inhibitory concentration of coumermycin A1 treatment completely inhibited the transcription of mRNA of *B. bovis* subunit B, but incompletely for the subunit A of DNA gyrase genes, in contrast to the control similar to *P. vivax* (Khor *et al.*, 2005), which is homologous to B-subunit of *B. bovis* (accession No.: XM_001611055) and *T. equi* (accession No.: XM_004833696). These outcomes recommend that DNA gyrase may be a potential target for coumermycin A1 in *Babesia* species and *T. equi*. Furthermore, it is an effective C-terminal inhibitor of 90 kDa heat shock proteins (Hsp90) in cancer cells and exhibits antiviral activity (Burlison and Blagg 2006; Vozzolo *et al.*, 2010; Kusuma *et al.*, 2011). The homologs of HSP90 from *B. bovis* HSP 90A (accession no. XM_001611817), *B. bovis* HSP 90B (accession No.: XM_001610712), *B. bigemina* HSP90 (accessions no.: CDR96732 and LK391707), *T. equi* HSP90A (accession no.: XM_004830871), and *T. equi* HSP90B (accession no.: XM_004833471) were found in the protein database of NCBI.

In this current work, Coumermycin A1 was found to have effective inhibitory effects on *T. equi* and *Babesia* species *in vitro*. Therefore, we decided to test whether this effect would also be observed during *B. microti* development in mice.

There was a 70.73% inhibition of *B. microti* growth. There were no indications of intoxication associated with the 5 mg/kg treatment, and the mice were alive during and post-experiment. In a previous study, mice were given coumermycin A1 two times a day, either 2 mg parentally or 4 mg orally, to treat experimental listeriosis (Hof *et al.*, 1986). The dose was 20-40 times greater than that used dose in the current study. Furthermore, it has been reported that coumermycin A1 did not disturb the normal functions of the immune system in treated mice (Tawfik, 1991).

Conclusions: In conclusion, coumermycin A1 inhibited growth effectively in *in-vitro* cultures of three *Babesia* species and *T. equi* and *in vivo* growth of *B. microti* in mice. Coumermycin A1 might be considered as a safe and effective anti-piroplasm agent for theileriosis and babesiosis.

Authors contribution: MA, AA, MAO and SM conceived and planned the experiments. MA, II, NY and MAO conducted the experiments. II, NY and MAOI provided reagents/materials/analysis tools. MA and MAO wrote the manuscript. All authors revised and accepted current manuscript version.

Funding: This study was sponsored by the Japan Society for the Promotion of Science (JSPS), as well as Ministry of Education, Culture, Science, and Technology, of Japan.

REFERENCES

- AbouLaila M, El-Sayed SAES, Omar MA, *et al.*, 2020. Myrrh oil *in vitro* inhibitory growth on bovine and equine piroplasm parasites and *Babesia microti* of mice. *Pathogens* 9:173.
- AbouLaila M, Abd El-Aziz A, Yokoyama N, *et al.*, 2019. Luteolin: target validation in *Babesia bovis* by reverse transcription-polymerase chain reaction and *in vivo* inhibition of *Babesia microti*. *J Clin Res Med Rep* 1:103.
- AbouLaila M, AbdEl-Aziz A, Menshaw S, *et al.*, 2019b. Evaluation of the *in vitro* and *in vivo* inhibitory effects of enrofloxacin on the growth of *Babesia* Species and *Theileria equi*. *J Drug Drug Abuse* 1:3-6.
- AbouLaila M, Abdelaziz A, Rizk M, *et al.*, 2019c. Evaluation of the *in vitro* and *in vivo* inhibitory effects of quercetin on the growth of *Babesia* and *Theileria* parasites. *Damanhour J Vet Sci* 2:23-7.
- AbouLaila M, Munkhjargal T, Sivakumar T, *et al.*, 2012. Apicoplast-targeting antibacterials inhibit the growth of *Babesia* parasites. *Antimicrob Agents Chemother* 56:3196-206.
- AbouLaila M, Nakamura K, Govind Y, *et al.*, 2010. Evaluation of the *in vitro* growth-inhibitory effect of epoxomicin on *Babesia* parasites. *Vet Parasitol* 167:19-27.
- Akram IN, Parveen T, Abrar A, *et al.*, 2019. Molecular detection of *Babesia microti* in dogs and cat blood samples collected from Punjab (Pakistan). *Trop Biomed* 36:304-9.
- Batiha GE, Beshbishy AM, Alkazmi L, *et al.*, 2020. Gas chromatography-mass spectrometry analysis, phytochemical screening and antiprotozoal effects of the methanolic *Viola tricolor* and acetic *Laurus nobilis* extracts. *BMC Complement Med Ther* 20:87.
- Balkaya I, Utuk AE and Piskin FC, 2010. Prevalance of *Theileria equi* and *Babesia caballi* in Donkeys from Eastern Turkey in Winter Season, *Pak Vet J* 30:245-6.
- Bonilla TD, 2008. Cellular functions of DNA gyrase and conditional gene regulation in the malaria parasite *Plasmodium falciparum*. University of Florida.
- Bork S, Okamura M, Boonchit S, *et al.*, 2004. Identification of *Babesia bovis* L-lactate dehydrogenase as a potential chemotherapeutic target against bovine babesiosis. *Mol Biochem Parasitol* 136:165-72.
- Brockelman C and Tan-ariya P, 1991. Development of an *in vitro* microtest to assess drug susceptibility of *Babesia bovis* and *Babesia bigemina*. *J Parasitol* 77:994-7.
- Burlison JA and Blagg BS, 2006. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. *Org Lett* 8:4855-8.
- Divo AA, Sartorelli AC, Patton CL, *et al.*, 1988. Activity of fluoroquinolone antibiotics against *Plasmodium falciparum* *in vitro*. *Antimicrob Agents Chemother* 32:1182-6.
- Hof H, 1986. The effect of coumermycin on experimental listeriosis. *J Infect* 13:17-23.
- Ica A, Vatansever Z, Yildirim A, *et al.*, 2007: Investigation of ovine blood protozoa by reverse line blotting in the Kayseri region. *Parasitologia* 49:90.
- Jabbar A, Abbas T, Sandhu Z, *et al.*, 2015. Tick-borne diseases of bovines in Pakistan: major scope for future research and improved control. *Parasit Vectors* 8:283.

- Khor V, Yowell C, Dame JB, et al., 2005: Expression and characterization of the ATP-binding domain of a malarial *Plasmodium vivax* gene homologous to the B-subunit of the bacterial topoisomerase DNA gyrase. *Mol Biochem Parasitol* 140:107-17.
- Kusuma BR, Peterson LB, Zhao H, et al., 2011. Targeting the heat shock protein 90 dimer with dimeric inhibitors. *J Med Chem* 54:6234-53.
- Li SM, Westrich L, Schmidt J, et al., 2002. Methyltransferase genes in *Streptomyces rishiriensis*: new coumermycin derivatives from gene-inactivation experiments. *Microbiol* 148:3317-26.
- Matsuu A, Yamasaki M, Xuan X, et al., 2008. *In vitro* evaluation of the growth inhibitory activities of 15 drugs against *Babesia gibsoni* (Aomori strain). *Vet Parasitol* 157:1-8.
- Munkhjargal T, AbouLaila M, Terkawi MA, et al., 2012. Inhibitory effects of pepstatin A and mefloquine on the growth of *Babesia* parasites. *Am J Trop Med Hyg* 87:68-688.
- Nichterlein T and Hof H, 1991. Effect of various antibiotics on *Listeria monocytogenes* multiplying in L 929 cells. *Infection* 19 Suppl 4:S234-8.
- Omar MA, Salama A, Elsify A, et al., 2016. Evaluation of *in vitro* inhibitory effect of enoxacin on *Babesia* and *Theileria* parasites. *Exp Parasitol* 161:62-7.
- Rizk MA, El-Sayed SAE, AbouLaila M, et al., 2017. Evaluation of the inhibitory effect of N-acetyl-L-cysteine on *Babesia* and *Theileria* parasites. *Exp Parasitol* 179:43-8.
- Rodriguez RI and Trees AJ, 1996. *In vitro* responsiveness of *Babesia bovis* to imidocarb dipropionate and the selection of a drug-adapted line. *Vet Parasitol* 62:35-41.
- Salama AA, AbouLaila M, Terkawi MA, et al., 2014. Inhibitory effect of allicin on the growth of *Babesia* and *Theileria equi* parasites. *Parasitol Res* 113:275-83.
- Tawfik AF, 1991. Effects of vancomycin, teicoplanin, daptomycin and coumermycin on normal immune capabilities. *J Chemother* 3:226-31.
- Topcu Z, 2001. DNA topoisomerases as targets for anticancer drugs. *J Clin Pharm Therapeut* 26:405-16.
- Vozzolo L, Loh B, Gane PJ, et al., 2010. Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein. *J Biol Chem* 285:39314-28.
- Zhao HF, Boyd J, Jolicoeur N, et al., 2003. A coumermycin/novobiocin-regulated gene expression system. *Hum Gene Ther* 14:1619-29.